SCHEMBL12360708

SCHEMBL12360708

CCC1OC(OC2C(C(=O)O)OC(OC3C(COS(=O)(=O)O)OC(O)C(C)C3O)C(OS(=O)(=O)O)C2O)C(C)C(O)C1OC1OC(C(=O)O)=CC(O)C1OS(=O)(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 4/20 0.46
▸ SERPINC1 P01008 2/20 0.40
▸ CXCL12 P48061 2/20 0.38
▸ CXCL10 P02778 1/20 0.38
▸ CXCL8 P10145 1/20 0.38
▸ CCL2 P13500 1/20 0.38
▸ CCL5 P13501 1/20 0.38
▸ BDNF P23560 3/20 0.36
▸ PTN P21246 2/20 0.36
▸ MDK P21741 2/20 0.36
▸ FGF2 P09038 3/20 0.35
▸ FGF1 P05230 2/20 0.35
▸ F8 P00451 1/20 0.33
▸ F9 P00740 1/20 0.33
▸ BMP2 P12643 1/20 0.33
▸ VEGFA P15692 1/20 0.33
▸ SHH Q15465 1/20 0.33
▸ HPSE Q9Y251 4/20 0.32
▸ F2 P00734 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041224 0.81 F10 (0.64) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL15395282 0.79 F10 (0.57) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL29647566 0.79 F10 (0.60) F10SERPINC1CXCL12CCL2BDNF
SCHEMBL16656874 0.78 F10 (0.52) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL15395243 0.78 F10 (0.56) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL15417563 0.78 F10 (0.53) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL16656905 0.77 F10 (0.63) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL12360709 0.76 F10 (0.62) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL15395281 0.76 F10 (0.55) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL16656323 0.76 F10 (0.55) F10SERPINC1CXCL12CXCL10CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003623-B2 Derived from heparin having a mean molecular weight of 1500-3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30; venous, arterial, or deep vein thromboses; pulmonary embolism; unstable angina; myocardial infarction; and cardiac ischemia AVENTIS PHARMA S.A. (FR) 2011-08-23 — — US disclosed
US-20080182820-A1 Mixtures of sulfated oligosaccharides AVENTIS PHARMA S.A. (FR) 2008-07-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182820-A1 Mixtures of sulfated oligosaccharides SERPINC1, HPSE, OSTC F10 31/4885SERPINC1 1/4885CXCL12 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback